Copyright Reports & Markets. All rights reserved.

Global Next-Generation Biologics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Next-Generation Biologics Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Antibodies
      • 1.4.3 Regenerative medicine
      • 1.4.4 Insulins
      • 1.4.5 Growth hormones
      • 1.4.6 Other
    • 1.5 Market by Application
      • 1.5.1 Global Next-Generation Biologics Market Share by Application (2014-2025)
      • 1.5.2 Medical
      • 1.5.3 Scientific Research
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Next-Generation Biologics Market Size
    • 2.2 Next-Generation Biologics Growth Trends by Regions
      • 2.2.1 Next-Generation Biologics Market Size by Regions (2014-2025)
      • 2.2.2 Next-Generation Biologics Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Next-Generation Biologics Market Size by Manufacturers
      • 3.1.1 Global Next-Generation Biologics Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Next-Generation Biologics Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Next-Generation Biologics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Next-Generation Biologics Key Players Head office and Area Served
    • 3.3 Key Players Next-Generation Biologics Product/Solution/Service
    • 3.4 Date of Enter into Next-Generation Biologics Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Next-Generation Biologics Market Size by Type (2014-2019)
    • 4.2 Global Next-Generation Biologics Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Next-Generation Biologics Market Size (2014-2019)
    • 5.2 Next-Generation Biologics Key Players in United States
    • 5.3 United States Next-Generation Biologics Market Size by Type
    • 5.4 United States Next-Generation Biologics Market Size by Application

    6 Europe

    • 6.1 Europe Next-Generation Biologics Market Size (2014-2019)
    • 6.2 Next-Generation Biologics Key Players in Europe
    • 6.3 Europe Next-Generation Biologics Market Size by Type
    • 6.4 Europe Next-Generation Biologics Market Size by Application

    7 China

    • 7.1 China Next-Generation Biologics Market Size (2014-2019)
    • 7.2 Next-Generation Biologics Key Players in China
    • 7.3 China Next-Generation Biologics Market Size by Type
    • 7.4 China Next-Generation Biologics Market Size by Application

    8 Japan

    • 8.1 Japan Next-Generation Biologics Market Size (2014-2019)
    • 8.2 Next-Generation Biologics Key Players in Japan
    • 8.3 Japan Next-Generation Biologics Market Size by Type
    • 8.4 Japan Next-Generation Biologics Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Next-Generation Biologics Market Size (2014-2019)
    • 9.2 Next-Generation Biologics Key Players in Southeast Asia
    • 9.3 Southeast Asia Next-Generation Biologics Market Size by Type
    • 9.4 Southeast Asia Next-Generation Biologics Market Size by Application

    10 India

    • 10.1 India Next-Generation Biologics Market Size (2014-2019)
    • 10.2 Next-Generation Biologics Key Players in India
    • 10.3 India Next-Generation Biologics Market Size by Type
    • 10.4 India Next-Generation Biologics Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Next-Generation Biologics Market Size (2014-2019)
    • 11.2 Next-Generation Biologics Key Players in Central & South America
    • 11.3 Central & South America Next-Generation Biologics Market Size by Type
    • 11.4 Central & South America Next-Generation Biologics Market Size by Application

    12 International Players Profiles

    • 12.1 Allergan
      • 12.1.1 Allergan Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Next-Generation Biologics Introduction
      • 12.1.4 Allergan Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.1.5 Allergan Recent Development
    • 12.2 Bayer
      • 12.2.1 Bayer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Next-Generation Biologics Introduction
      • 12.2.4 Bayer Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.2.5 Bayer Recent Development
    • 12.3 Biogen Idec
      • 12.3.1 Biogen Idec Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Next-Generation Biologics Introduction
      • 12.3.4 Biogen Idec Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.3.5 Biogen Idec Recent Development
    • 12.4 Eli Lilly
      • 12.4.1 Eli Lilly Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Next-Generation Biologics Introduction
      • 12.4.4 Eli Lilly Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.4.5 Eli Lilly Recent Development
    • 12.5 Kyowa Hakko Kirin
      • 12.5.1 Kyowa Hakko Kirin Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Next-Generation Biologics Introduction
      • 12.5.4 Kyowa Hakko Kirin Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.5.5 Kyowa Hakko Kirin Recent Development
    • 12.6 Molecular Partners
      • 12.6.1 Molecular Partners Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Next-Generation Biologics Introduction
      • 12.6.4 Molecular Partners Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.6.5 Molecular Partners Recent Development
    • 12.7 Novo Nordisk
      • 12.7.1 Novo Nordisk Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Next-Generation Biologics Introduction
      • 12.7.4 Novo Nordisk Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.7.5 Novo Nordisk Recent Development
    • 12.8 Pfizer
      • 12.8.1 Pfizer Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Next-Generation Biologics Introduction
      • 12.8.4 Pfizer Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.8.5 Pfizer Recent Development
    • 12.9 Roche
      • 12.9.1 Roche Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Next-Generation Biologics Introduction
      • 12.9.4 Roche Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.9.5 Roche Recent Development
    • 12.10 Sanofi
      • 12.10.1 Sanofi Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Next-Generation Biologics Introduction
      • 12.10.4 Sanofi Revenue in Next-Generation Biologics Business (2014-2019)
      • 12.10.5 Sanofi Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Next generation biologics refers to some noval drugs, biotreatment and some breakthroght biomaterials etc.
      The increasing demand for antibody drug conjugates (ADCs) is one of the major factors driving this market’s growth. ADCs are highly effective cytotoxic drugs linked to an mAbs. These drugs have shown to be potent and efficient in treating diseases, including cancers and hematological malignancies.
      In 2018, the global Next-Generation Biologics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Next-Generation Biologics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Next-Generation Biologics development in United States, Europe and China.

      The key players covered in this study
      Allergan
      Bayer
      Biogen Idec
      Eli Lilly
      Kyowa Hakko Kirin
      Molecular Partners
      Novo Nordisk
      Pfizer
      Roche
      Sanofi

      Market segment by Type, the product can be split into
      Antibodies
      Regenerative medicine
      Insulins
      Growth hormones
      Other

      Market segment by Application, split into
      Medical
      Scientific Research
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Next-Generation Biologics status, future forecast, growth opportunity, key market and key players.
      To present the Next-Generation Biologics development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Next-Generation Biologics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now